Showing results (111-120 of 279) with videos related to
Sort By:
Pageof 28
The Journal of Clinical Investigation|October 26, 2010
hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processingRachel Wilson Goehe, Jacqueline C Shultz, Charuta Murudkar, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2014
A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancerBenjamin Levy, Alexander Spira, Daniel Becker, et al.Cancer|September 12, 2013
Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapyD Ross Camidge, Margaret Skokan, Porntip Kiatsimkul, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2016
Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap AnalysisSinéad A Noonan, Lynne Berry, Xian Lu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2017
Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the LungSinead A Noonan, Tejas Patil, Dexiang Gao, et al.Clinical Lung Cancer|October 4, 2018
Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR InhibitorElena Helman, Minh Nguyen, Chris A Karlovich, et al.ESMO Open|August 13, 2022
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studiesC A Powell, S Modi, H Iwata, et al.Cancer|November 8, 2014
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancerRobert C Doebele, David Spigel, Mustapha Tehfe, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2012
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancerAndrew J Weickhardt, Benjamin Scheier, Joseph Malachy Burke, et al.Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinibLeora Horn, Scott Gettinger, D Ross Camidge, et al.Pageof 28